

Key Trend Revolutionizing The Carcinoma Tumor Market In 2025: Pivoting Towards Innovation In Diagnostic Technologies

The Business Research Company's Key Trend Revolutionizing The Carcinoma Tumor Market In 2025: Pivoting Towards Innovation In Diagnostic Technologies

LONDON, GREATER LONDON, UNITED KINGDOM, March 24, 2025

[/EINPresswire.com/](https://EINPresswire.com/) -- Updated 2025

Market Reports Released: Trends,

Forecasts to 2034 – Early Purchase Your Competitive Edge Today!



Global attention is placing the carcinoma tumor market at the forefront of healthcare investment, inciting rapid expansion and exciting development breakthroughs. The market size has grown expeditiously from \$1.61 billion in 2024 to an estimated \$1.78 billion in 2025, recording a Compound Annual Growth Rate CAGR of 10.7%. The upward trajectory during the historical period is credited to the increasing incidence of neuroendocrine tumors, rising awareness about rare cancers, improved healthcare infrastructure, availability of targeted therapies, and the expansion of clinical trials for new treatment options.

“

It will grow to \$2.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%.”

The Business Research Company

Can the Carcinoid Market Maintain its Impressive Growth Momentum?

The exponential growth witnessed in the carcinoid tumor market is only the tip of the iceberg with predictions estimating that the market will escalate to \$2.65 billion in 2029 at a CAGR of 10.5%. Boosting the forecast period growth is the escalating demand for personalized medicine, a focused approach to early detection and diagnosis, the adoption of minimally invasive surgeries, and extensive research on groundbreaking therapies and molecular targeted therapies. These key drivers are intertwined with significant forecast period trends such as the integration of AI and machine learning in diagnostics, a shift towards combination therapies, the proliferation of telemedicine and remote monitoring, patient-centric care, and collaborative

research.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp>

What is Fueling the Fast-Paced Growth of the Carcinoid Tumor Market?

An unexpected tailwind comes from the growing obese population, expected to turbocharge the growth of the carcinoid tumor market. Obesity, defined as having a Body Mass Index BMI of 30 or higher due to excessive body fat, has been linked to an increase in carcinoid tumor development by fostering chronic inflammation, insulin resistance, and increased secretion of growth factors that support tumor growth. Factors behind the growing obesity population include poor dietary habits, a lack of physical activity, sedentary lifestyles, and increased consumption of processed and high-calorie foods. Notably, data from the Centers for Disease Control and Prevention reveals that in 2022, 22 states reported an adult obesity rate of 35% or higher, an increase from 19 states in 2021. This underscores the significant role of the growing obese population in driving the growth of the carcinoid tumor market.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report>

Who Are The Giants Shaping The Carcinoid Tumor Market?

Significant contributors and shapers of the Carcinoid tumor market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited A subsidiary of HUTCHMED, Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., and Dauntless Pharmaceuticals Inc.

Are There Any Emerging Trends in the Carcinoid Tumor Market?

In a bid to maintain a competitive edge, major players are pivoting towards innovation in diagnostic technologies. A prime example is the development of the fully automated chromogranin A test, designed to enhance early detection and improve treatment outcomes. The automated chromogranin A CgA test stands as a game-changer in diagnostics, used to measure levels of chromogranin A, a biomarker frequently associated with neuroendocrine tumors, including carcinoid tumors. A product of this endeavor includes the recent FDA-clearance of Thermo Fisher Scientific Inc.'s Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay.

How is The Carcinoid Tumor Market Segmented?

By Disease Type:

- Gastrointestinal Neuroendocrine Tumor
- Pancreatic Neuroendocrine Tumor
- Lung Neuroendocrine Tumor
- Other Disease Types

By Treatment:

- Octreotide
- Lanreotide
- Telotristat ethyl
- Capecitabine Xeloda
- 5-Fluorouracil 5-FU
- Doxorubicin Adriamycin
- Etoposide VP-16
- Dacarbazine DTIC
- Streptozocin
- Other Treatments

By Route Of Administration:

- Oral
- Parenteral
- Other Routes Of Administration

By Distribution Channel:

- Online Channel
- Offline Channel

By End User:

- Hospital And Clinics
- Academic Institutions
- Research Organizations

Subsegments:

- By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors
- By Pancreatic Neuroendocrine Tumor: Insulinoma, Non-insulinoma, Glucagonoma
- By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors, Atypical Carcinoid Tumors
- By Other Disease Types: Thymic Neuroendocrine Tumors, Ovarian Neuroendocrine Tumors

Which Regions Dominate The Carcinoid Tumor Market?

In the year 2024, North America dominated the carcinoid tumor market with Asia-Pacific positioned as the fastest-growing region in the forecast period. The report covers all regions

including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse For More Similar Reports-

Tumor Embolization Devices Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report>

Cancer Immunotherapy Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report>

Cancer Vaccines Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report>

The carcinoid tumor market report is one among thousands of high-quality reports from [The Business Research Company](#). Be part of our trusted clientele who benefits from our innate ability to provide data-rich research coupled with in-depth industry insights across 27 industries and 60+ geographies.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/796561350>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.